When semaglutide further impairs absorption, the math gets ugly fast
HR: 0.56, 95% CI: 0.420.75)
Theres a basic breakdown of some options in checkout, but not all treatment options are visible until you pay and access the patient portal
It does not contain all the available information
This can be challenging for people who take other morning medications, can't wait 30 minutes for breakfast, or have trouble following such a strict morning routine
Results of the SURMOUNT-5 trial (ClinicalTrials.gov Identifier: NCT05822830), which evaluated the efficacy and safety of tirzepatide (dual GIP/GLP-1 RA) compared with semaglutide (GLP-1 RA) in adults with obesity or overweight, at least one weight-related comorbidity but no T2D, are in process and expected to be presented and published in 2025